CAS 668270-12-0
:Linagliptin
Description:
Linagliptin is an oral antihyperglycemic agent primarily used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as DPP-4 inhibitors, which work by increasing incretin levels, thereby enhancing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. This mechanism helps to lower blood glucose levels without causing significant hypoglycemia. Linagliptin is characterized by its high selectivity for the DPP-4 enzyme, which contributes to its efficacy and safety profile. The substance is typically administered once daily due to its long half-life, allowing for convenient dosing. Linagliptin is also notable for its minimal renal excretion, making it suitable for patients with renal impairment. In terms of chemical properties, it has a molecular formula that reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. Overall, Linagliptin is recognized for its effectiveness in glycemic control and its favorable tolerability profile in diabetic patients.
Formula:C25H28N8O2
InChI:InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
InChI key:InChIKey=LTXREWYXXSTFRX-QGZVFWFLSA-N
SMILES:C(C#CC)N1C2=C(N=C1N3C[C@H](N)CCC3)N(C)C(=O)N(CC4=NC5=C(C(C)=N4)C=CC=C5)C2=O
Synonyms:- (R)-8-[3-Aminopiperidin-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazolin-2-ylmethyl)xanthine
- 1H-Purine-2,6-Dione, 8-[(3R)-3-Amino-1-Piperidinyl]-7-(2-Butyn-1-Yl)-3,7-Dihydro-3-Methyl-1-[(4-Methyl-2-Quinazolinyl)Methyl]-
- 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-
- 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
- 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
- 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
- Bi 1356
- Bi 1356Bs
- Ondero
- Tradjenta
- Trajenta
- See more synonyms
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Linagliptin
CAS:Formula:C25H28N8O2Purity:>98.0%(HPLC)(T)Color and Shape:White to Light yellow powder to crystalMolecular weight:472.55Linagliptin
CAS:Drugs containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structureFormula:C25H28N8O2Color and Shape:White Light Yellow Yellow PowderMolecular weight:472.23352Linagliptin
CAS:Linagliptin (BI 1356) is a potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity.Formula:C25H28N8O2Purity:99.64% - >99.99%Color and Shape:Yellow SolidMolecular weight:472.54Linagliptin
CAS:Formula:C25H28N8O2Purity:≥ 98.0% (anhydrous basis)Color and Shape:White, off-white or pale orange-yellow powderMolecular weight:472.54Linagliptin (Standard)
CAS:Linagliptin (Standard) is a reference standard for research and analysis in studies involving Linagliptin. Linagliptin (BI 1356) is a potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity.Formula:C25H28N8O2Molecular weight:472.54Linagliptin Methyl Dimer
CAS:Controlled ProductApplications Linagliptin Methyldimer is an impurity of Linagliptin (L465900). Linagliptin is a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
References Prabavathy, N. et al.: Int. J. Pharm. Bio. Sci., 2, 438 (2011); Deacon, C.F.: Diab. Obes. Metab., 13, 7 (2011)Formula:C51H56N16O4Color and Shape:NeatMolecular weight:957.095Linagliptin
CAS:Applications Linagliptin is a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
References Prabavathy, N. et al.: Int. J. Pharm. Bio. Sci., 2, 438 (2011); Deacon, C.F.: Diab. Obes. Metab., 13, 7 (2011);Formula:C25H28N8O2Color and Shape:NeatMolecular weight:472.54N-Nitroso Linagliptin Impurity 91
CAS:Formula:C24H25N9O3Color and Shape:Yellow SolidMolecular weight:487.52N-Nitroso Linagliptin Impurity 14
CAS:Formula:C45H43N15O5Color and Shape:Yellow SolidMolecular weight:873.94(R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
CAS:(R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dioneFormula:C25H28N8O2Purity:99%Molecular weight:472.54
